Lifestyle Modification or Medication to Improve Condition of Patients With Asymptomatic Heart Failure - Monitoring and Management of OptiVol Alert to Reduce Heart Failure Hospitalization II (MOMOTARO II) Study

Circ J. 2020 Feb 25;84(3):456-462. doi: 10.1253/circj.CJ-19-0986. Epub 2020 Feb 8.

Abstract

Background: In heart failure (HF) patients implanted with high-energy devices, worsening of HF can be diagnosed from intrathoracic impedance (ITI) before symptoms appear. Early therapeutic intervention can prevent HF worsening, but the optimal intervention remains unknown. This study aimed to examine which lifestyle modifications or medications can improve HF indicators in asymptomatic HF patients diagnosed from ITI.Methods and Results:This multicenter, prospective, randomized study included patients with high-energy devices, left ventricular ejection fraction <40%, or with a history of HF hospitalization. After the OptiVol alert was evoked by decreased ITI, patients underwent examinations. If they were diagnosed with HF, they were randomly assigned to 3 groups: lifestyle modification, diuretic, or nitrate. After 1 week, they underwent the same examinations. The primary endpoint was change in ITI and serum B-type natriuretic peptide (BNP). Totally, 57 patients were randomized. In all 3 groups, ITI was significantly increased post-intervention compared with pre-intervention. In the diuretic and nitrate groups, logBNP post-intervention was significantly lower than pre-intervention, but not in the lifestyle modification group.

Conclusions: Compared with lifestyle modifications, diuretic and nitrate therapy for 1 week may be more effective management of HF detected by decreased ITI. However, lifestyle modification may have the additional benefits of reducing the workload or cost.

Keywords: B-type natriuretic peptide; Intrathoracic impedance; Lifestyle modification; OptiVol alert; Remote monitoring.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Asymptomatic Diseases
  • Biomarkers / blood
  • Diuretics / adverse effects
  • Diuretics / therapeutic use*
  • Female
  • Heart Failure / diagnosis
  • Heart Failure / mortality
  • Heart Failure / physiopathology
  • Heart Failure / therapy*
  • Humans
  • Japan
  • Male
  • Middle Aged
  • Natriuretic Peptide, Brain / blood
  • Nitrates / adverse effects
  • Nitrates / therapeutic use*
  • Patient Admission
  • Peptide Fragments / blood
  • Prospective Studies
  • Recovery of Function
  • Risk Factors
  • Risk Reduction Behavior*
  • Time Factors
  • Treatment Outcome
  • Vasodilator Agents / adverse effects
  • Vasodilator Agents / therapeutic use*

Substances

  • Biomarkers
  • Diuretics
  • Nitrates
  • Peptide Fragments
  • Vasodilator Agents
  • pro-brain natriuretic peptide (1-76)
  • Natriuretic Peptide, Brain